Eosinophilic Granulomatosis with Polyangiitis (EGPA) Clinical Trials

EGPA is classified as an ANCA-associated vasculitis alongside granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), though it is distinguished by its eosinophil-driven pathology and near-universal association with asthma. The disease involves both eosinophil-mediated tissue damage (through release of major basic protein, eosinophil cationic protein, and other toxic granule contents) and vasculitis (inflammation and necrosis of blood vessel walls). Clinically, EGPA is divided into two phenotypes.

The most common symptoms of Eosinophilic Granulomatosis with Polyangiitis include Severe adult-onset asthma that is difficult to control, Chronic sinusitis and nasal polyps, Peripheral neuropathy (numbness, tingling, weakness in hands or feet), Skin findings including purpura, nodules, and urticarial rash, Heart problems including myocarditis, pericarditis, and heart failure, among others. Eosinophilic Granulomatosis with Polyangiitis affects approximately 10 to 14 cases per million people; approximately 3,000 to 4,500 individuals in the U.S. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Eosinophilic Granulomatosis with Polyangiitis from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. With mepolizumab (2017) and benralizumab (2024) both FDA-approved for EGPA, patients now have two targeted options, but many questions remain open. Trials are comparing anti-IL-5 agents head-to-head, studying steroid-free remission maintenance, and investigating whether early biologic initiation can prevent irreversible nerve or heart damage.

Yes. As of October 21, 2026, 2 FDA-approved medicines have a current label that names Eosinophilic Granulomatosis with Polyangiitis: Fasenra (benralizumab), first approved in 2024; and Nucala (mepolizumab), first approved in 2017. Corticosteroids and immune globulins count once each.

The exact cause of Eosinophilic Granulomatosis with Polyangiitis is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. ANCA-positive in 30-50%; cause is multifactorial and there is no gene test. The condition affects approximately 10 to 14 cases per million people; approximately 3,000 to 4,500 individuals in the U.S. Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Eosinophilic Granulomatosis with Polyangiitis. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. ANCA-positive in 30-50%; cause is multifactorial and there is no gene test.

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Eosinophilic Granulomatosis with Polyangiitis clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Eosinophilic Granulomatosis with Polyangiitis clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.